Suchergebnisse
Suchergebnisse:
Vor 5 Tagen · Solaris has engaged ESSAM Cía. Ltda., an Ecuadorian environmental consulting firm accredited by Ecuador’s Ministry of Environment, to finalize and submit the EIA for the Warintza exploitation phase. ESSAM has experience supporting Ecuador’s largest copper and gold mines. The EIA submission is targeted for the second half of 2024, building on over three years of baseline environmental ...
Vor 3 Tagen · Stability with Solaris 55. “There is an aggressive increase in form stability with special treatment in the forward zones, where local righting moments rise quickly with heeling,” Acebal ...
Vor 4 Tagen · Usage statistics of Solaris for websites. These diagrams show the usage statistics of Solaris as operating system on the web. See technologies overview for explanations on the methodologies used in the surveys. Our reports are updated daily. Solaris is used by less than 0.1% of all the websites whose operating system we know.
Vor 3 Tagen · Solaris is also present at the trade fair and invites visitors to its booth D22 D26 G21 G27 in Fiera Milano hall, where the hydrogen bus – Urbino 12 hydrogen – is showcased. This is the manufacturer’s most popular hydrogen model – over 200 buses of this type are in operation across 10 European countries, including Bolzano and Venice, Italy. Furthermore, the company has an order ...
Vor 6 Tagen · A high-level overview of Solaris Resources Inc. (SLSSF) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.
Vor 4 Tagen · About Subcutaneous OLAnzapine Extended-Release Injection Study (SOLARIS) SOLARIS is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety, and tolerability of olanzapine extended-release injectable suspension for subcutaneous use as a treatment in patients (ages 18-65 years) with schizophrenia.
Vor 4 Tagen · About Subcutaneous OLAnzapine Extended-Release Injection Study (SOLARIS) SOLARIS is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety, and tolerability of olanzapine extended-release injectable suspension for subcutaneous use as a treatment in patients (ages 18-65 years) with schizophrenia.
